½ÃÀ庸°í¼­
»óǰÄÚµå
1376876

ü¿Ü½Ä Á¦¼¼µ¿±â ½ÃÀå ±Ô¸ð : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, ¿¹Ãø(2023-2032³â)

External Defibrillators Market Size By Product (Manual External Defibrillator, Automated External Defibrillator, Wearable External Cardioverter Defibrillator), By End-use, & Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ü¿Ü½Ä Á¦¼¼µ¿±â ½ÃÀå ±Ô¸ð´Â ÀÀ±ÞÀÇ·á¼­ºñ½º ¹× ÇコÄÉ¾î ½Ã¼³¿¡¼­ Á¶±â Á¦¼¼µ¿ Áß½ÃÀÇ Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÇ¸ç, 2023-2032³â CAGR 7.4%·Î È®´ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÀ´ä ½Ã°£ ´ÜÃà, º´¿ø Àü ÀÀ±Þ½Ã¼ú °­È­, ȯÀÚ ¿¹ÈÄ °³¼±¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÀ±ÞÀÇ·á ÇöÀå¿¡¼­ ÈÞ´ë¿ë Á¦¼¼µ¿±âÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÚµ¿ ü¿Ü Á¦¼¼µ¿±â(AED)ÀÇ »ç¿ë ÆíÀǼº°ú È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â ÷´Ü ±â´É°ú ½º¸¶Æ®ÇÑ ±â´ÉÀ» °®Ãá ÀÚµ¿ Á¦¼¼µ¿±â(AED)ÀÇ °³¹ß µî Á¦¼¼µ¿±â ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 1¿ù Avive Solutions´Â ¹Ì±¹ FDA·ÎºÎÅÍ ÈÞ´ëÆù, WiFi, GPS, ºí·çÅõ½º ¿¬°á µî ÷´Ü ±â´ÉÀ» °®Ãá Çõ½ÅÀûÀÎ AEDÀÎ Avive AEDTMÀÇ ½ÃÆÇ Àü ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù.

ü¿Ü Á¦¼¼µ¿±â »ê¾÷Àº Á¦Ç°, ÃÖÁ¾ ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î º¸¸é ¿þ¾î·¯ºí ü¿Ü Á¦¼¼µ¿±â ½ÃÀåÀº Áö¼ÓÀûÀÎ ½ÉÀå ¸ð´ÏÅ͸µ°ú ½Å¼ÓÇÑ Á¦¼¼µ¿ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖÀ¸¸ç, 2023-2032³â Å« °ßÀηÂÀ» È®º¸ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñħ½ÀÀûÀÌ°í ¿þ¾î·¯ºíÇÑ µðÀÚÀΰú ¿þ¾î·¯ºí ü¿Ü Á¦¼¼µ¿±â°¡ Á¦°øÇÏ´Â È޴뼺°ú »ç¿ëÀÚ Ä£È­Àû ÀÎ Á¶ÀÛÀÌ °áÇյǾî ÀÓ»ó ¹× ºñÀÓ»ó ȯ°æ¿¡¼­ÀÇ Àû¿ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø Àü Áø·á ºÐ¾ßÀÇ Ã¼¿Ü Á¦¼¼µ¿±â »ê¾÷ÀÌ 2023-2032³â »ó´çÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±¸±ÞÂ÷, ÀÀ±ÞÀÇ·á ¼­ºñ½º, ±¸±Þ´ë µî º´¿ø Àü ȯ°æ¿¡¼­ ½Å¼ÓÇÑ Á¦¼¼µ¿ÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÈÞ´ë¿ë ¹× »ç¿ëÇϱ⠽¬¿î ü¿Ü Á¦¼¼µ¿±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ °á°ú °³¼±, ´ëÀÀ ½Ã°£ ´ÜÃà, ÀÀ±ÞÀÇ·á °­È­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ º´¿ø Àü ½ÉÀå Ä¡·á ¹× °ü¸® ºÐ¾ß¿¡¼­ Á¦Ç° äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ã¼¿Ü Á¦¼¼µ¿±â »ê¾÷Àº 2032³â±îÁö °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±× ¹è°æ¿¡´Â ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÀÌ Áö¿ªÀÇ ½ÉÀå ÀÀ±Þ ½Ã¼ú¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁöÁöÀûÀÎ ±ÔÁ¦ Á¤Ã¥, °©ÀÛ½º·± ½ÉÀ帶ºñ °ü¸®¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀ» ³ôÀ̱â À§ÇÑ Á¤ºÎÀÇ ±¸»ó, °ø°øÀå¼Ò¿¡ Á¦¼¼µ¿±â ¼³Ä¡ Àǹ«È­ µîÀÌ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÏ·Ê·Î, 2023³â 6¿ù Àεµ ¿ìŸ¸£ ÇÁ¶óµ¥½Ã ÁÖ Á¤ºÎ´Â ¸ðµç ¼îÇθô°ú Á¤ºÎ û»ç¿¡ AED¸¦ ¼³Ä¡ÇÏ¿© ½ÉÁ¤Áö ȯÀÚ¿¡°Ô ÇÊ¿äÇÑ ÀÀ±Þ½Ã¼ú¸¦ Á¦°øÇϰڴٴ °èȹÀ» ¹ßÇ¥Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ü¿Ü½Ä Á¦¼¼µ¿±â »ê¾÷ ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ½ÉÁúȯÀÇ À¯º´·ü »ó½Â
      • ±â¼úÀÇ Áøº¸¿Í Çõ½ÅÀû ±â±âÀÇ ¼­·Ð
      • ÀÏ¹Ý ½Ã¹Î ÀǽÄÀÇ Çâ»ó
      • ¿þ¾î·¯ºí Á¦¼¼µ¿±â¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ±â±âÀÇ °íºñ¿ë
      • Á¦Ç° ¸®ÄÝ
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • »óȯ ½Ã³ª¸®¿À
  • °¡°Ý ºÐ¼®, 2022³â
  • Á¦Ç° ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ±â¼ú Àü¸Á
  • ½Å±Ô ±â¾÷ ½Ã³ª¸®¿À
  • °¸ ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • º¥´õ¡¤¸ÅÆ®¸¯½º ºÐ¼®
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ü¿Ü½Ä Á¦¼¼µ¿±â ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä Á¦Ç° µ¿Çâ
  • ¼öµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â
  • ÀÚµ¿ ü¿Ü½Ä Á¦¼¼µ¿±â
    • ¹ÝÀÚµ¿ ü¿Ü½Ä Á¦¼¼µ¿±â
    • ÀüÀÚµ¿ ü¿Ü½Ä Á¦¼¼µ¿±â
  • ÀåÂøÇü ü¿Ü½Ä Á¦¼¼µ¿±â

Á¦6Àå ü¿Ü½Ä Á¦¼¼µ¿±â ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä ÃÖÁ¾ ¿ëµµ µ¿Çâ
  • º´¿ø
  • ÇÁ¸®È£½ºÇÇÅ» Äɾî
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦7Àå ü¿Ü½Ä Á¦¼¼µ¿±â ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Áö¿ª µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • Æú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦8Àå ±â¾÷ °³¿ä

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Koninklijke Philips
  • Stryker Corporation
  • Medtronic plc
  • LivaNova PLC
  • Asahi Kasei Corporation(ZOLL Medical Corporation)
  • Nihon Kohden Corporation
  • MicroPort Scientific Corporation
  • Element Science Inc.
  • AMI Italia
  • Bexen Cardio
  • BPL Medical Technologies
  • Corpuls
  • Schiller AG
KSA 23.11.15

External Defibrillators Market size is set to expand at 7.4% CAGR from 2023-2032 driven by the increasing emphasis on early defibrillation in emergency medical services and healthcare facilities.

The growing attention to reducing response times, enhancing prehospital care, and improving patient outcomes is surging the adoption of portable and user-friendly defibrillation devices in emergency medical settings. Furthermore, the ongoing advancements in defibrillator technology, including the development of automated external defibrillators (AEDs) with advanced features and smart functionalities for improved device usability and efficacy will contribute to market growth. For instance, in January 2023, Avive Solutions received pre-market approval from the U.S. FDA for Avive AEDTM, its innovative AED with advanced features, such as cellular, WiFi, GPS, and Bluetooth connection.

The external defibrillators industry is segmented into product, end-use, and region.

Based on product, the wearable external cardioverter defibrillators market is foreseen to gain significant traction between 2023 and 2032 attributed to their ability to provide continuous cardiac monitoring and prompt defibrillation therapy. The non-invasive and wearable designs coupled with the portability and user-friendly operations offered by wearable external cardioverter defibrillators is spurring their application in clinical and non-clinical settings.

Based on end-use, the external defibrillators industry from the prehospital care segment is likely to depict considerable growth from 2023-2032. The thriving need for prompt defibrillation in prehospital settings, including ambulances, emergency medical services, and first responder units is surging the demand for portable and user-friendly external defibrillators. Additionally, the increasing focus on improving patient outcomes, reducing response times, and enhancing emergency medical care is further contributing to the increasing product adoption in prehospital cardiac care and management.

Asia Pacific external defibrillators industry is estimated to witness robust growth through 2032. This is driven by the increasing prevalence of cardiovascular diseases, expanding geriatric population base, and the rising awareness of cardiac emergency management in the region. Moreover, the supportive regulatory policies, the government initiatives for promoting public awareness about sudden cardiac arrest management, and mandates for defibrillator installation in public spaces is driving the regional market growth. To cite an instance, in June 2023, the government of Uttar Pradesh in India announced plans to install AEDs at all malls, and government buildings to provide necessary first aid to patients in case of cardiac arrest.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Industry coverage
  • 1.2 Market scope & definitions
  • 1.3 Base estimates & working
    • 1.3.1 Data collection
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact at global level
  • 1.6 Data validation
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 External defibrillator industry 360 degree synopsis, 2018 - 2032
  • 2.2 Business trends
  • 2.3 Regional trends
  • 2.4 Product trends
  • 2.5 End-use trends

Chapter 3 External Defibrillator Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cardiac diseases
      • 3.2.1.2 Technological advancements and introduction of innovative devices
      • 3.2.1.3 Increasing public awareness
      • 3.2.1.4 Surging demand for wearable cardioverter defibrillators
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of the devices
      • 3.2.2.2 Product recalls
  • 3.3 Growth potential analysis
    • 3.3.1 By product
    • 3.3.2 By end-use
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
  • 3.6 Reimbursement scenario
  • 3.7 Pricing analysis, 2022
  • 3.8 Product pipeline analysis
  • 3.9 Technology landscape
  • 3.10 Startup scenario
  • 3.11 Gap analysis
  • 3.12 Porter's analysis
  • 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Company market share analysis, 2022
  • 4.4 Competitive positioning matrix
  • 4.5 Vendor matrix analysis
  • 4.6 Strategy dashboard, 2022

Chapter 5 External Defibrillator Market Size and Forecast, By Product (USD Million & Units)

  • 5.1 Key product trends
  • 5.2 Manual External Defibrillator
  • 5.3 Automated External Defibrillator
    • 5.3.1 Semi-automated external defibrillator
    • 5.3.2 Fully automated external defibrillator
  • 5.4 Wearable External Cardioverter Defibrillator

Chapter 6 External Ddefibrillator Market Size and Forecast, By End-use (USD Million)

  • 6.1 Key end-use trends
  • 6.2 Hospitals
  • 6.3 Prehospital Care
  • 6.4 Ambulatory Surgical Centers
  • 6.5 Others

Chapter 7 External defibrillator Market Size and Forecast, By Region (USD Million & Units)

  • 7.1 Key regional trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Poland
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Indonesia
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 Middle East & Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE

Chapter 8 Company Profiles

  • 8.1 Abbott Laboratories, Inc.
  • 8.2 Boston Scientific Corporation
  • 8.3 Koninklijke Philips
  • 8.4 Stryker Corporation
  • 8.5 Medtronic plc
  • 8.6 LivaNova PLC
  • 8.7 Asahi Kasei Corporation (ZOLL Medical Corporation)
  • 8.8 Nihon Kohden Corporation
  • 8.9 MicroPort Scientific Corporation
  • 8.10 Element Science Inc.
  • 8.11 AMI Italia
  • 8.12 Bexen Cardio
  • 8.13 BPL Medical Technologies
  • 8.14 Corpuls
  • 8.15 Schiller AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦